Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial cancer
• * Stage III or IV disease
• * Metastatic peritoneal, lymphatic, or visceral disease
• Measurable or evaluable disease
• Previously untreated disease OR relapsed disease more than 6 months after the completion of a platinum-containing chemotherapy regimen
• No symptomatic brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 to 75
• Performance status
• WHO 0-2 (0 in patients 70 to 75 years of age)
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin no greater than 1.25 times upper limit of normal (ULN)
• AST and ALT no greater than 3 times ULN
• Alkaline phosphatase less than 2.5 times ULN
• Renal
• Creatinine no greater than 1.4 mg/dL
• Other
• No serious uncontrolled infection
• No intolerance to polysorbate 80
• No peripheral neuropathy greater than grade 1
• No neurological or mental disease that would preclude study participation
• No other prior malignancy except curatively treated basal cell skin cancer or carcinoma in situ of the cervix
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• See Disease Characteristics
• More than 4 weeks since prior chemotherapy
• No more than 1 prior chemotherapy regimen
• No prior oxaliplatin or docetaxel
• Endocrine therapy
• Not specified
• Radiotherapy
• More than 4 weeks since prior radiotherapy
• Surgery
• Not specified
• Other
• More than 28 days since prior participation in another clinical study
• No other concurrent anticancer treatment